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Foreword
The female pelvic reproductive organs continue to be a major site for cancer and a
major cause of mortality among American women. The past year has seen the news
media focus attention on the role of the Pap smear in the diagnosis of cervical cancer.
The untimely death ofGilda Radner has led to the public's awareness ofthe virulence
of ovarian cancer. The Seventh Annual Ella T. Grasso Memorial Conference will
concentrate on the diagnosis and treatment ofcervical and ovarian cancer.
The Pap smear has been the mainstay in the early diagnosis of cervical cancer.
Nevertheless, a small group of women will develop cervical cancer despite having a
recent negative Pap smear. These so-called "rapidly progressive cervical cancers," i.e.,
cervical cancers that occur within a short time following a negative Pap smear, are
presented in the Proceedings. Attention is now being directed to the endocervical canal
as the site of origin of the cancer. One paper recommends the use of cytologic brush
techniques to obtain endocervical scrapings in order to improve the efficacy of the
routine Pap smear, reduce the incidence of rapidly progressive cervical cancer, and
improve the results oftherapy for this aggressive disease.
The epidemiology, treatment, and staging of the common epithelial ovarian cancer
continues to be ofgreat importance, as ovarian cancer most often presents as Stage III
or IV disease, i.e., disease that has spread into the upper abdomen or beyond the
peritoneal cavity at the time of initial diagnosis. Tumors of borderline malignant
potential are an unusual variant of epithelial ovarian cancers. These tumors have the
capacity to metastasize, yet patients' survival is outstanding with surgical resection
only. A paper in the Proceedings from Yale University School of Medicine reviews a
recent large experience with borderline malignant potential tumors and their manage-
ment and emphasizes conservative treatment for this disease.
Early diagnosis ofgynecologic malignancies remains critical for successful manage-
ment. The role of monoclonal antibodies in the diagnosis and treatment of ovarian
cancer is extremely important for practicing physicians as well as for basic scientists.
Two new gynecologic cancer markers, the urinary gonadotropin fragment and colony
stimulating factor-1, have been developed in part at the Yale University School of
Medicine. Their initial clinical trials at this institution are presented in an effort to
develop methods of recognizing the presence of ovarian cancer before the patient is
symptomatic and for use as tumor markers to influence treatment.
One ofthe most successful new approaches for the management ofovarian cancer is
intraperitoneal chemotherapy. The intraperitoneal routeallows the physician to expose
cancer cells to the highest possible concentration of chemotherapy, yet allows the
patient to experience reduced toxicity, in comparison to intravenous treatment.
Intraperitoneal therapy appears to bethe most effective treatment for the management
of persistent or recurrent ovarian cancer when it is present to a limited degree, and
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this type of therapy is currently being considered for initial treatment. A review of
intraperitoneal chemotherapy completes this issue ofthe Proceedings.
The annual Ella T. Grasso Memorial Conference has provided an outstanding
vehicle for updating physicians in Connecticut and throughout the region with
state-of-the-art diagnosis and treatment for gynecologic malignancies. I am indebted
to the authors for submitting their manuscripts to The YaleJournaland to theJournal
for providing us with the opportunity to publish the papers prior to the conference.
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